Skip to main content

Table 2 Summary of reports in literature (continued)

From: Breast carcinoma with choriocarcinomatous features: a case report and review of the literature

Patients ER PR Ki-67 EMA PLAP P53 Follow-up Metastasis Treatment References
1 + + DFS Lung, kidney S + C Present study
2 / + + / Died Lung, chest wall, liver S + C + R + E [7]
3 + / / / / / No S [9]
4 / / / / / / Died Left parietal lobe C + R [10]
5 + + / / DFS No S [11]
6 / 100 / / DFS No S + C [8]
7 / / / / Died Back neck, Pelvis, lungs S + C [8]
8 + 17 / Lost / S + C + R [3]
9 + 40 / + DFS No S + C + R [3]
10 + 10 / + DFS No S + C + R [3]
11 2 / Lost / S [3]
12 / / / / / / Died Lung, Lymph nodes S [4]
13 / / / / / / DFS Lymph nodes S + E [12]
14 / / / / / / / Lungs, skin C [13]
15 +80% / / DFS No S [14]
16 +80% / / + DFS No S [14]
17 / / / / / / S + C [15]
18 / / / / / / Died Lung, Liver, Kidneys C [5]
  1. “+”, Positive; “–”, Negative; “/”, Unknown. “Lost”, Lost to follow-up.
  2. L, Left breast; R, Right breast; LN, Lymph node status; IDC-DCIS, Infiltrating ductal carcinoma-ductal carcinoma in situ; HPL, Human placental lactogen; HCG, Human chorionic gonadotropin; CK, Cytokeratin; ER, Estrogen receptor; PR, Progesterone receptor; EMA, Epithelial membrane antigen; PALP, Placental alkaline phosphatase; DFS, Disease free survival; S, Surgery; C, Chemotherapy; R, Radiotherapy; E, Endocrine therapy.